Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;10(2):1114-1121.
doi: 10.1002/ehf2.14277. Epub 2022 Dec 30.

Predictors of bleeding events in acute decompensated heart failure patients with antithrombotic therapy: AURORA study

Shodai Kawanami  1 , Yasuyuki Egami  1 , Hiroki Sugae  1 , Kohei Ukita  1 , Akito Kawamura  1 , Hitoshi Nakamura  1 , Yutaka Matsuhiro  1 , Koji Yasumoto  1 , Masaki Tsuda  1 , Naotaka Okamoto  1 , Yasuharu Matsunaga-Lee  1 , Masamichi Yano  1 , Masami Nishino  1 , Jun Tanouchi  1
Affiliations

Predictors of bleeding events in acute decompensated heart failure patients with antithrombotic therapy: AURORA study

Shodai Kawanami et al. ESC Heart Fail. 2023 Apr.

Abstract

Aims: Heart failure (HF) is reported to be one of the major risks of bleeding events. On the other hand, HF patients frequently receive anticoagulants or antiplatelet therapy to manage various co-morbidities. However, predictors of bleeding events in patients with HF have rarely been reported. This study aimed to evaluate the predictors of bleeding events and relationship between bleeding events and HF re-hospitalizations.

Methods and results: We included 1660 acute decompensated heart failure (ADHF) patients from the AURORA registry between January 2015 and December 2020. A total of 1429 patients were excluded because of history of HF admission, missing echocardiographic data at discharge, lost to follow-up, haemodialysis and no antithrombotic drugs. Finally, we evaluated 231 patients from AURORA registry. The bleeding events were defined as Type 2 to 5 bleeding according to the Bleeding Academic Research Consortium definition. We divided our patients into the bleeding group and non-bleeding group. We compared the baseline characteristics, medications, laboratory data, and echocardiographic data between the two groups. Median age was 78 (IQR 71-82) years old and male accounted for 59%. Approximately half of the patients had an antiplatelet therapy and 70% had an anticoagulant therapy. During a median follow-up of 651 (IQR 357-1139) days, 32 patients (13.8%) suffered from bleeding events. The major driver of the registered events was gastrointestinal bleeding (n = 21, 65.6%), and the other events were cerebral bleeding (n = 4, 12.5%), intraarticular bleeding (n = 2, 6.3%), urogenital bleeding (n = 2, 6.3%), haemorrhagic pericardial effusions (n = 1, 3.1%), subcutaneous hematomas (n = 1, 3.1%), and haemothorax (n = 1, 3.1%). There was a significantly lower haemoglobin level (P < 0.01), higher proportion of inferior vena cava (IVC) diameter ≥21 mm (P < 0.01), and higher furosemide equivalent doses per kilogram (P < 0.01) in the bleeding group than non-bleeding group. A multivariate analysis revealed an equivalent dose of furosemide per kilogram ≥0.66 mg/kg (hazard ratios (HR) of 2.64, 95% confidence interval (CI) 1.26-5.68, P = 0.01), haemoglobin ≤10.3 g/dL (HR of 2.43, 95% CI 1.14-5.03, P = 0.02), and IVC diameter ≥21 mm (HR of 2.79, 95% CI 1.16-6.29, P = 0.02) were independently associated with bleeding events. The Kaplan-Meier analysis showed that HF re-hospitalization rates were higher in the bleeding group than non-bleeding group (P = 0.04).

Conclusions: High doses of oral loop diuretics, IVC dilatation, and anaemia were predictors of bleeding events in patients hospitalized with ADHF patients. In addition, bleeding events were associated with HF re-hospitalizations.

Keywords: ADHF; Anaemia; Bleeding events; High dose loop diuretics; IVC.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
Flow chart of the study patients. ADHF, acute decompensated heart failure.
Figure 2
Figure 2
Freedom from heart failure re‐hospitalization rate between the bleeding and non‐bleeding groups.
See this image and copyright information in PMC

References

    1. Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, Wilson PW, Ohman EM, Brennan DM, D'Agostino RB, Bhatt DL, Steg PG. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J. 2010; 31: 1257–1265. - PMC - PubMed
    1. Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yoshikawa Y, Shiomi H, Nakagawa Y, Furukawa Y, Kadota K, Ando K, Akasaka T, Hanaoka KI, Kozuma K, Tanabe K, Morino Y, Muramatsu T, Kimura T. Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO‐Kyoto thrombotic and bleeding risk scores. J Am Heart Assoc. 2018; 7: e008708. - PMC - PubMed
    1. Pozzoli M, Gonzalez‐Costello J, Bayes‐Genis A, Sinagra G, Anker SD, Coats AJS, Crespo‐Leiro MG, Filippatos G, Laroche C, Maggioni AP, Mebazaa A, Piepoli MF, Tavazzi L. Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. Eur J Heart Fail. 2020; 22: 906–910. - PubMed
    1. Yoshihisa A, Kanno Y, Ichijo Y, Sato Y, Takiguchi M, Yokokawa T, Abe S, Misaka T, Sato T, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Takeishi Y. Incidence and subsequent prognostic impacts of gastrointestinal bleeding in patients with heart failure. Eur J Prev Cardiol. 2020; 27: 664–666. - PubMed
    1. Nochioka K. Simplifying bleeding risk assessment in heart failure. Circ J. 2021; 86: 156, CJ‐21‐0921–157. - PubMed